View Item 

Show simple item record

Evaluation of menogaril in renal cell carcinoma
dc.contributor.authorStephens, Ronald L.en_US
dc.contributor.authorGoodman, Phyllisen_US
dc.contributor.authorCrawford, E. Daviden_US
dc.contributor.authorSpicer, Connie F.en_US
dc.contributor.authorLowe, Bruce A.en_US
dc.contributor.authorAhmann, Frederick R.en_US
dc.contributor.authorChapman, Roberten_US
dc.contributor.authorNatale, Ronald B.en_US
dc.date.accessioned2006-09-11T15:57:06Z
dc.date.available2006-09-11T15:57:06Z
dc.date.issued1990-03en_US
dc.identifier.citationStephens, Ronald L.; Goodman, Phyllis; Crawford, E. David; Spicer, Connie F.; Lowe, Bruce A.; Ahmann, Frederick R.; Chapman, Robert; Natale, Ronald B.; (1990). "Evaluation of menogaril in renal cell carcinoma." Investigational New Drugs 8(1): S69-S71. <http://hdl.handle.net/2027.42/45344>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45344
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2143177&dopt=citationen_US
dc.description.abstractThe Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m 2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.en_US
dc.format.extent251137 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherMenogarilen_US
dc.subject.otherRenal Cell Carcinomaen_US
dc.titleEvaluation of menogaril in renal cell carcinomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, USAen_US
dc.contributor.affiliationotherUniversity of Kansas Medical Center, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Group Statistical Center, USAen_US
dc.contributor.affiliationotherUniversity of Colorado, USAen_US
dc.contributor.affiliationotherUniversity of Kansas Medical Center, USAen_US
dc.contributor.affiliationotherOregon Health Sciences University, Arizona, USAen_US
dc.contributor.affiliationotherUniversity of Arizona, USAen_US
dc.contributor.affiliationotherHenry Ford Hospital, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2143177en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45344/1/10637_2004_Article_BF00171987.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00171987en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00171987.pdf
Size:
245.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.